



NEWS RELEASE

Dr. Roland Bürli Joins Novation's Scientific Advisory Board

FOR IMMEDIATE RELEASE

January 19, 2022

Port Coquitlam, Canada: Novation Pharmaceuticals Inc. announced today that Dr. Roland Bürli has joined Novation's Scientific Advisory Board (SAB).

Dominique Cheneval, CEO of Novation said that "We are excited to have Dr. Bürli join our SAB. He brings to Novation his vast scientific and large Pharma expertise. Trained as a synthetic and medicinal chemist, Dr. Bürli's drug discovery experience in various therapeutic areas will provide invaluable assets to Novation as the Company advances its small molecule ALS program. His knowledge in pre-clinical and clinical development in the neuroscience and inflammation therapeutic areas will definitely be a significant contribution to Novation. We are very much looking forward to working with Dr. Bürli as Novation continues to further develop and utilize its *Quest* technology."

About Novation and its *Quest* Technology

Novation is a product-focused company that identifies new therapeutics for a broad range of diseases, including neurodegeneration. The Company developed *Quest*, its breakthrough drug-discovery technology that harnesses the natural cellular control function of mRNA modulation. The technology uses cell-based assays to identify small molecules that impact protein expression via mRNA modulation.

The ability to affect mRNA function with small molecular weight compounds can impact a wide range of disease areas from therapeutic intervention, including "non-drugable" targets, to diseases currently treated with biologicals. As a non-biased approach, *Quest* can identify both inhibitory and stimulatory small molecule compounds that modulate the stability of a target mRNA or influence its translatability.

Novation's suite of *Quest* drug-discovery assays span a number of disease areas, with targets in oncology, inflammation, cardiometabolic, neurodegeneration and dyslipidemia. Novation is also developing assays for COVID-19 and other areas where there is a great need for small molecule therapeutics.

This news release contains certain forward looking statements. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the inherent risks associated with drug research and development, difficulties or delays in development testing, changes in regulatory affairs, lack of therapeutic efficacy, unacceptable side-effects, the dependence on partners, the inability to raise sufficient finance, the appearance of competitors and other risks generally associated with the biopharmaceutical industry.

For further information contact:

Dominique Cheneval, Ph.D.
CEO and Co-Founder
Novation Pharmaceuticals Inc.
104 - 2071 Kingsway Avenue
Port Coquitlam, B.C., Canada V3C 6N2
Telephone: 604.552.0768
Email: dcheneval@novation-pharma.com
Web site: www.novation-pharma.com